Gene Testing Firm Renhe Future Secures RMB 250 Million Series A Funding to Strengthen Big Data and Precision Health Initiatives

2017Year12June 26, Renhe Future AnnouncesAWheelFinancing2.5100 million yuan. According to VCBeat (WeChat ID: vcbeat),This RoundFunded on2017Year7Completed in [Month],The investors are Jiawo Capital and Haijie Capital.

Founded in 2014, Renhe Future is a genetic technology company. As a National Demonstration Center for Genetic Testing Technology and a Center for Genetic Big Data Application Engineering, the company leverages the dual drivers of biotechnology (BT) and information technology (IT) to achieve industry-leading multi-dimensional innovations. Through efficient industrial transformation and collaborative mechanisms, it overcomes barriers to commercialization in the genetics sector, dedicating itself to promoting and guiding technological innovation and application development in health, medicine, big data, and artificial intelligence, while providing personalized products and solutions.

The rise of second-generation sequencing technologies and the decline in sequencing costs have led to the widespread adoption of genetic testing in both clinical practice and the market. Molecular-level genetic analyses have deepened medical understanding of human genetic mechanisms and diseases. In turn, these insights have further driven the expansion and application of genomic technologies.

The latest frontier for genetic technology is obstetrics and gynecology, where non-invasive prenatal testing (NIPT) has sparked a revolution in clinical prenatal screening, emerging as a powerful tool for controlling birth defects. Meanwhile, with technological advancements and the gradual establishment of market awareness and regulatory frameworks, genetic testing is poised to create even greater waves in the field of oncology.

Originating in “non-invasive” applications and flourishing in “oncology”—this may well be the best interpretation of gene technology’s clinical medical utility. Likewise, these represent two strategic focus areas for Renhe Future in the medical field.

Currently, the company’s medical diagnostics primarily serve maternal and infant populations, while also providing solutions for personalized diagnosis and treatment of cancer. The company’s independently developed core liquid biopsy technology, “ctBEST,” achieves a detection sensitivity of 0.01%. Its proprietary “non-invasive single-gene disorder screening” technology is also poised for imminent launch.

Beyond clinical-grade diagnostic assistance, integrating genetic technologies to digitize life and achieve precision health management may represent the ultimate goal of genetic technology for human health. In the realm of smart health management, Renhe Future has integrated multi-dimensional vital sign data with healthcare decision support models and machine learning to launch a product line and platform system for personalized disease risk assessment and intelligent health management.

Renhe Future not only provides genetic testing services such as susceptibility testing, gut microbiome analysis, and early cancer screening, but also integrates a health management system with a Clinical Decision Support System (CDSS). By incorporating machine-driven intelligent diagnostics, it empowers the health management platform with expert-level diagnostic and therapeutic capabilities, as well as a platform-wide personalized intervention framework.

As sequencing technology becomes increasingly market-driven and commercialized, it will inevitably create both bottlenecks and opportunities in downstream data processing. Since its inception, the company has strategically positioned itself to provide innovative technical solutions for genomic big data. Leveraging its integrated BT (Biotechnology) + IT (Information Technology) advantages, the company has independently developed a comprehensive solution spanning multiple stages of big data management, including high-performance data transmission, compression, storage, computation, interpretation, and mining, thereby delivering end-to-end big data services.

Following this round of financing, Renhe Future will accelerate the clinical translation and market promotion across three key sectors: regulatory approval for diagnostic and early-screening reagents; cloud platform development and deployment for big data services among industry users; and the implementation and marketing of its AI-powered precision health platform.

It is reported that the post-money valuation of Renhe Future has reached RMB 2.75 billion after this round of financing.